Knowledge Center

Article / Jul 27, 2015

Hovione and Invion sign development agreement for first inhaled non-steroidal anti-inflammatory for asthma

Authors:
Source:
Manufacturing Chemist, 27 July 2015

Portuguese API manufacturer Hovione has agreed with Invion to progress the development of inhaled INV104 (zafirlukast) as a potential new treatment for asthma.

Hovione and the Australian drug developer will collaborate to develop the proprietary novel technology – a dry powder formulation of the compound INV104 (zafirlukast) delivered by Hovione’s inhaler.

Related links

Read article here

Also in the Knowledge Center

Related Content

Enhanced process understanding

Ensuring enhanced understanding through state of the art methodologies and technologies.

Page
Read more

Corticosteroids

Corticosteroids are produced in two dedicated buildings on the Loures site, which are equipped with vessels ranging from 50L up to 4000L.

Page
Read more

Covid-19 / Coronavirus

Stay updated with the latest information on Covid-19

Page
Read more